Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy (ULSPABIT)

Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting First Time or Switching to a New Biological Therapy; the ULSpABiT Study.

Patients with spondylarthritis (SpA) (including ankylosing spondylitis, psoriatic arthritis, arthritis as part of inflammatory bowel disease and reactive arthritis) have axial involvement (the spine) as well as peripheral inflammation in joints and entheses (where the tendons and ligaments are anchored to the bone). Patients with high disease activity of SpA may need biological treatment (anti-TNF alpha), which are very expensive medications. Thus it is necessary to have a sensitive method for assessing the response to treatment. Ultrasonography (US) is a validated and reliable method for assessing disease activity in joints and tendons, and may be used to follow the treatment response.

The present study will include patients with SpA starting on anti-TNF alpha treatment (as first biologic medication or when switching to a new biologic treatment). The study is an extension of the ongoing NORDMARD study (Norwegian longitudinal observational study of arthritic patients starting disease-modifying treatment). The patients will be examined by use of US of 38 joints and 14 entheses at baseline and after 3, 6 and 12 months.

The objectives are to explore US as a method to assess peripheral inflammatory activity for evaluation of response to medication as well as to compare the US pathology with clinical and laboratory findings.

Study Overview

• Status: Completed
• Conditions: Ultrasonography; Spondyloarthritis
• Intervention / Treatment: Biological: Anti-TNF alpha therapy

• Study Type: Observational
• Enrollment (Actual): 50

Contacts and Locations

Study Locations

• Norway
  • Oslo, Norway, 0319
    • Department of Rheumatology, Diakonhjemmet Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

SpA patients with high disease activity

Description

Inclusion Criteria:

• SpA
• Planning to start anti-TNF alpha treatment

Exclusion Criteria:

• Patients not being able to communicate in Norwegian or not being able to fill in questionnaires
• Surgery in more than 5 of the joints/entheses to be examined by US

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
SpA patients; The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.	Biological: Anti-TNF alpha therapy; All medical treatment will be standardizes following good medical practice; Other Names: Adalimumab (HumiraR); Etanercept (EnbrelR); Infliximab (RemicadeR); Golimumab (SimponiR)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the sensitivity to change of US pathology in joints and entheses in SpA patients starting biological treatment.	The joints will be assessed according to a US atlas by use of a semi-quantitative (0-3) scoring system and the entheses will be evaluated according to internationally accepted scoring methods.	Including patients for about 1.5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1. Explore whether the US (B-mode and power Doppler) scores at baseline or after 3 months predict patients responding to biological treatment after 6 and 12 months.		2.5 years
2. Explore whether the sensitivity for change is higher for US (B-mode and/or power Doppler) than for the traditional assessments for inflammatory activity.		2.5 years
3. Explore potential differences of US detected pathology in joints and entheses between subgroups of spondylarthritis patients.		2.5 years
4. Explore whether the different subgroups of spondylarthritis patients have different US response (B-mode synovitis and power Doppler in joints and entheses) to biological treatment.		2.5 years
5. Explore the association between the US findings (BM and/or PD) and the patient's experience of pain and fatigue.		2.5 years
6. Explore the associations between calprotectin and US detected inflammation in joints and/or entheses as well as traditional assessments of disease activity.	Calprotectin, a major granulocyte protein, is assessed by use of ELISA in plasma. Plasma samples will be frozen at all visits, and the calprotectin assessments will be performed when all patients have finished the study.	2.5 years
7. Explore whether baseline calprotectin or other biomarkers in blood may predict response to biological medication.	Plasma and serum will be frozen at each visit, and the S100 proteins calprotectin as well as A12 will be assessed. In addition, other relevant biomarkers may be analyzed after 2.5 years.	2.5 years

Collaborators and Investigators

• Sponsor: Diakonhjemmet Hospital
• Investigators: Principal Investigator: Hilde B Hammer, MD, PhD, Diakonhjemmet Hospital

Study record dates

Study Major Dates

• Study Start: September 1, 2011
• Primary Completion (Actual): January 1, 2016
• Study Completion (Actual): January 1, 2016

Study Registration Dates

• First Submitted: September 15, 2010
• First Submitted That Met QC Criteria: October 12, 2010
• First Posted (Estimate): October 13, 2010

Study Record Updates

• Last Update Posted (Actual): August 2, 2022
• Last Update Submitted That Met QC Criteria: August 1, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: Ultrasonography; Synovitis; SpA; Enthesitis; Anti-TNF alpha treatment
• Additional Relevant MeSH Terms: Infections; Joint Diseases; Musculoskeletal Diseases; Arthritis; Spinal Diseases; Bone Diseases; Bone Diseases, Infectious; Spondylitis; Spondylarthritis; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Immunosuppressive Agents; Immunologic Factors; Gastrointestinal Agents; Dermatologic Agents; Tumor Necrosis Factor Inhibitors; Etanercept; Adalimumab; Infliximab; Golimumab
• Other Study ID Numbers: 011110